[Clinical experiences in patients with coronary heart disease and angina pectoris].
Publications dealing with the results of treating coronary heart disease patients with 5-(3-tert-butylamino-2-hydroxy-propoxy)-3, 4-dihydro-2(1H)-quinolinone hydrochloride (carteolol hydrochloride, Endak, Endak mite) are reviewed. They amount to 7 publications dealing with a total of 137 patients. Heart rate, blood pressure, pressure-rate product, behaviour of the S-T depression under exercise, together with the subjective declarations of the number of angina pectoris attacks and the use of nitroglycerin were used to evaluate the effectivity. The therapeutically effective doses lay between 6 and 20 mg per day. Carteolol increased the tolerance of stress by 45%, in an ergometric investigation, as compared with a placebo. The reduction of the S-T depression, typical of an anti-anginal effect, was observed in all investigations with carteolol. Carteolol reduced the increase in the arterial blood pressure under stress and lowered the raised pressure-rate product. Carteolol significantly reduced the heart rate on exercise. Tachycardiac resting rates became normal, normal rates remained unchanged. A bradycardia of less than 50 beats/min was not observed in any of the patients. Only 9 of the 137 patients suffered from side-effects and the treatment had to be terminated in just 2 cases. Pathological alterations were not revealed by the clinical laboratory investigations during any of the studies.
D000787:Angina Pectoris / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D002354:Carteolol / Q000009:adverse effects / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy*; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D005996:Nitroglycerin / Q000494:pharmacology; D011412:Propanolamines / Q000627:therapeutic use*
D011412:Propanolamines; D002354:Carteolol; D005996:Nitroglycerin
Klinische Erfahrungen bei Patienten mit koronarer Herzerkrankung und Angina pectoris.